Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma

References

• Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–13. doi:10.1038/35000501.
   PubMed Web of Science ®Google Scholar
• Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nature Medicine. 2018;24(5):679–690. doi:10.1038/s41591-018-0016-8.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, and Giltnane JM , et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. Lymphoma/Leukemia Molecular Profiling. The New England Journal of Medicine. 2002;346(25), 1937–1947. DOI: 10.1056/NEJMoa012914.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. The New England Journal of Medicine. 2018;378(15):1396–1407. doi:10.1056/NEJMoa1801445.
   PubMed Web of Science ®Google Scholar
• Basso K, Dalla-Favera R. Germinal centres and B cell lymphomagenesis. Nature Reviews Immunology. 2015;15(3):172–184. doi:10.1038/nri3814.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Dalla-Favera R. SnapShot: diffuse large B cell lymphoma. Cancer Cell. 2014;25(132–132):e131. doi:10.1016/j.ccr.2013.12.012.
   Google Scholar
• Pasqualucci L, Dalla-Favera R. The genetic landscape of diffuse large B-cell lymphoma. Semin Hematol. 2015;52(2):67–76. doi:10.1053/j.seminhematol.2015.01.005.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040–2045. doi:10.1182/blood-2010-03-276246.
   PubMed Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808. doi:10.1182/blood-2017-03-769620.
   PubMed Web of Science ®Google Scholar
• Hashwah H, Bertram K, Stirm K, Stelling A, Wu CT, Kasser S, Manz MG, Theocharides AP, Tzankov A, Muller A. The IL −6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B-cell lymphoma. EMBO Molecular Medicine. 2019;11(10):e10576. doi:10.15252/emmm.201910576.
   PubMed Web of Science ®Google Scholar
• Meier C, Hoeller S, Bourgau C, Hirschmann P, Schwaller J, Went P, Pileri SA, Reiter A, Dirnhofer S, Tzankov A. Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc. 2009;22(3):476–487. doi:10.1038/modpathol.2008.207.
   PubMed Web of Science ®Google Scholar
• Ok CY, Chen J, Xu-Monette ZY, Tzankov A, Manyam GC, Li L, Visco C, Montes-Moreno S, Dybkaer K, Chiu A, et al. Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2014;20(19):5113–5123. doi:10.1158/1078-0432.CCR-14-0683.
   PubMed Web of Science ®Google Scholar
• Tzankov A, Leu N, Muenst S, Juskevicius D, Klingbiel D, Mamot C, Dirnhofer S. Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study. Journal of Hematology & Oncology. 2015;8(1):70. doi:10.1186/s13045-015-0168-7.
   PubMed Web of Science ®Google Scholar
• Buchert M, Burns CJ, Ernst M. Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene. 2016;35(8):939–951. doi:10.1038/onc.2015.150.
   PubMed Web of Science ®Google Scholar
• Lu L, Zhu F, Zhang M, Li Y, Drennan AC, Kimpara S, Rumball I, Selzer C, Cameron H, and Kellicut A, et al. () Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America. 2018;115: E498–E505
   Google Scholar
• Gupta M, Han JJ, Stenson M, Maurer M, Wellik L, Hu G, Ziesmer S, Dogan A, Witzig TE. Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. Blood. 2012;119(12):2844–2853. doi:10.1182/blood-2011-10-388538.
   PubMed Web of Science ®Google Scholar
• Beguelin W, Sawh S, Chambwe N, Chan FC, Jiang Y, Choo JW, Scott DW, Chalmers A, Geng H, Tsikitas L, et al. IL10 receptor is a novel therapeutic target in DLBCLs. Leukemia. 2015;29(8):1684–1694. doi:10.1038/leu.2015.57.
   PubMed Web of Science ®Google Scholar
• Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115–119. doi:10.1038/nature09671.
   PubMed Web of Science ®Google Scholar
• Phelan JD, Young RM, Webster DE, Roulland S, Wright GW, Kasbekar M, Shaffer AL 3rd, Ceribelli M, Wang JQ, Schmitz R, et al. A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature. 2018;560(7718):387–391. doi:10.1038/s41586-018-0290-0.
   PubMed Web of Science ®Google Scholar
• Hashwah H, Schmid CA, Kasser S, Bertram K, Stelling A, Manz MG, and Muller A. () Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth. Proceedings of the National Academy of Sciences of the United States of America. 2017;114: 9701–9706
   Google Scholar
• Stelling A, Hashwah H, Bertram K, Manz MG, Tzankov A, Muller A. The tumor suppressive TGF-beta/SMAD1/S1PR2 signaling axis is recurrently inactivated in diffuse large B-cell lymphoma. Blood. 2018;131(20):2235–2246. doi:10.1182/blood-2017-10-810630.
   PubMed Web of Science ®Google Scholar
• Das R, Strowig T, Verma R, Koduru S, Hafemann A, Hopf S, Kocoglu MH, Borsotti C, Zhang L, Branagan A, et al. Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice. Nature Medicine. 2016;22(11):1351–1357. doi:10.1038/nm.4202.
   PubMed Web of Science ®Google Scholar
• Menter T, Ernst M, Drachneris J, Dirnhofer S, Barghorn A, Went P, Tzankov A. Phenotype profiling of primary testicular diffuse large B-cell lymphomas. Hematological Oncology. 2014;32(2):72–81. doi:10.1002/hon.2090.
   PubMed Web of Science ®Google Scholar
• Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. The Journal of Experimental Medicine. 1988;167(2):353–371. doi:10.1084/jem.167.2.353.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282. doi:10.1182/blood-2003-05-1545.
   PubMed Web of Science ®Google Scholar
• Obermann EC, Csato M, Dirnhofer S, Tzankov A. Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment. Journal of Clinical Pathology. 2009;62(8):754–756. doi:10.1136/jcp.2009.065227.
   PubMed Web of Science ®Google Scholar
• Tzankov A, Heiss S, Ebner S, Sterlacci W, Schaefer G, Augustin F, Fiegl M, Dirnhofer S. Angiogenesis in nodal B cell lymphomas: a high throughput study. Journal of Clinical Pathology. 2007;60:476–482. doi:10.1136/jcp.2006.038661.
   PubMed Web of Science ®Google Scholar
• Juskevicius D, Jucker D, Klingbiel D, Mamot C, Dirnhofer S, Tzankov A. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort. Journal of Hematology & Oncology. 2017;10(1):70. doi:10.1186/s13045-017-0438-7.
   PubMed Web of Science ®Google Scholar
• Carpenter RL, Lo HW. STAT3 Target Genes Relevant to Human Cancers. Cancers. 2014;6(2):897–925. doi:10.3390/cancers6020897.
   PubMed Web of Science ®Google Scholar
• Snyder M, Huang XY, Zhang JJ. Identification of novel direct Stat3 target genes for control of growth and differentiation. The Journal of Biological Chemistry. 2008;283(7):3791–3798. doi:10.1074/jbc.M706976200.
   PubMed Web of Science ®Google Scholar
• Ouyang W, O’Garra A. IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation. Immunity. 2019;50(4):871–891. doi:10.1016/j.immuni.2019.03.020.
   PubMed Web of Science ®Google Scholar
• Menter T, Dickenmann M, Juskevicius D, Steiger J, Dirnhofer S, Tzankov A. Comprehensive phenotypic characterization of PTLD reveals potential reliance on EBV or NF-kappaB signalling instead of B-cell receptor signalling. Hematological Oncology. 2017a;35(2):187–197. doi:10.1002/hon.2280.
   PubMed Web of Science ®Google Scholar
• Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, Zhang Y, Cattoretti G, Ye BH. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood. 2008;111(3):1515–1523. doi:10.1182/blood-2007-04-087734.
   PubMed Web of Science ®Google Scholar
• Rongvaux A, Willinger T, Martinek J, Strowig T, Gearty SV, Teichmann LL, Saito Y, Marches F, Halene S, Palucka AK, et al. Development and function of human innate immune cells in a humanized mouse model. Nature Biotechnology. 2014;32(4):364–372. doi:10.1038/nbt.2858.
   PubMed Web of Science ®Google Scholar
• Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM, Jack RS, Wunderlich FT, Bruning JC, Muller W, et al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity. 2011;34(4):566–578. doi:10.1016/j.immuni.2011.03.018.
   PubMed Web of Science ®Google Scholar
• Murai M, Turovskaya O, Kim G, Madan R, Karp CL, Cheroutre H, Kronenberg M. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nature Immunology. 2009;10(11):1178–1184. doi:10.1038/ni.1791.
   PubMed Web of Science ®Google Scholar
• Naing A, Infante JR, Papadopoulos KP, Chan IH, Shen C, Ratti NP, Rojo B, Autio KA, Wong DJ, Patel MR, et al. PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8(+) T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients. Cancer Cell. 2018;34(775–791):e773. doi:10.1016/j.ccell.2018.10.007.
   Google Scholar
• Menter T, Juskevicius D, Alikian M, Steiger J, Dirnhofer S, Tzankov A, and Naresh KN. Mutational landscape of B-cell post-transplant lymphoproliferative disorders. British Journal of Haematology. 2017;178:48–56.
   PubMed Web of Science ®Google Scholar